and Myelin Oligodendrocyte Glycoprotein (MOG). However, each person with NMOSD will experience different symptoms, and each will require individually tailored care and support. Changing the game ...

Roche said that NMOSD will be launched in two weeks. This approval is supported by results from two randomised controlled phase 3 trials, the SAkuraStar and SAkuraSky studies.

The drug is already approved in the US to treat the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD). The FDA’s latest decision was supported by results from the phase 3 MITIGATE ...

A swift and accurate diagnosis is crucial when treating any disease, but especially a rare one. Sadly, people with particularly rare diseases that present like more recognisable conditions face a ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire ...